Get the Stockscreener App
8.36
9.07%
0.695
After Hours:
8.36
Actuate Therapeutics Inc stock is traded at $8.36, with a volume of 58,818.
It is up +9.07% in the last 24 hours and up +33.55% over the past month.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
See More
Previous Close:
$7.665
Open:
$7.71
24h Volume:
58,818
Relative Volume:
0.57
Market Cap:
$171.13M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+2.96%
1M Performance:
+33.55%
6M Performance:
+8.71%
1Y Performance:
+3.85%
1-Day Range:
$7.4878
$8.36
1-Week Range:
$7.46
$8.57
52-Week Range:
$5.47
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Name
Actuate Therapeutics Inc
Sector
Industry
Phone
847-986-4190
Address
1751 RIVER RUN, FORT WORTH
Compare ACTU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
8.36 | 168.88M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Craig Hallum | Buy |
| Mar-17-25 | Initiated | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Stock (ACTU) Latest News
Short interest data insights for Actuate Therapeutics Inc.Earnings Risk Summary & Low Drawdown Trading Strategies - Newser
Published on: 2025-08-21 00:13:55 - thegnnews.com
Why Actuate Therapeutics Inc. is moving todayWeekly Trade Recap & Intraday High Probability Alerts - Newser
Does Actuate Therapeutics Inc. fit your quant trading model2025 Buyback Activity & Risk Controlled Stock Alerts - Newser
Sentiment analysis tools applied to Actuate Therapeutics Inc.July 2025 Final Week & Growth-Oriented Investment Plans - Newser
What makes Actuate Therapeutics Inc. stock price move sharplyJuly 2025 Analyst Calls & Free Long-Term Investment Growth Plans - Newser
Forecasting Actuate Therapeutics Inc. price range with options dataFed Meeting & Daily Risk Controlled Trade Plans - Newser
Will Actuate Therapeutics Inc. stock recover after recent dropWeekly Loss Report & Reliable Trade Execution Plans - Newser
Visual trend scoring systems applied to Actuate Therapeutics Inc.Treasury Yields & Real-Time Stock Entry Alerts - Newser
Real time pattern detection on Actuate Therapeutics Inc. stockJuly 2025 Sector Moves & Stepwise Entry/Exit Trade Alerts - Newser
When is the best time to exit Actuate Therapeutics Inc.Earnings Growth Report & Stepwise Entry/Exit Trade Alerts - Newser
Actuate Therapeutics Inc. Uptrend in Early Stages Indicators Say YesJuly 2025 Movers & Weekly Top Performers Watchlists - beatles.ru
Regression analysis insights on Actuate Therapeutics Inc. performanceWeekly Investment Summary & Free Real-Time Volume Trigger Notifications - Newser
Has Actuate Therapeutics Inc. found a price floor2025 Market Sentiment & Consistent Income Trade Ideas - Newser
Can Actuate Therapeutics Inc. recover in the next quarter2025 Momentum Check & Expert Curated Trade Setup Alerts - Newser
How institutional ownership impacts Actuate Therapeutics Inc. stockEarnings Growth Report & Stepwise Swing Trade Plans - Newser
Can volume confirm reversal in Actuate Therapeutics Inc.2025 Historical Comparison & Stock Portfolio Risk Management - Newser
Detecting price anomalies in Actuate Therapeutics Inc. with AIJuly 2025 Breakouts & Daily Technical Stock Forecast Reports - Newser
Smart tools for monitoring Actuate Therapeutics Inc.’s price actionJuly 2025 Action & Free Long-Term Investment Growth Plans - Newser
Risk adjusted return profile for Actuate Therapeutics Inc. analyzedPortfolio Risk Report & AI Driven Price Forecasts - Newser
Published on: 2025-08-19 06:14:55 - Newser
Comparing Actuate Therapeutics Inc. in custom built stock radars2025 Price Targets & AI Forecast Swing Trade Picks - Newser
Ewing Sarcoma Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com
Visualizing Actuate Therapeutics Inc. stock with heatmaps2025 Top Gainers & Daily Price Action Insights - Newser
Will Actuate Therapeutics Inc. stock split in the near futureTrade Risk Report & Risk Controlled Daily Plans - Newser
How to read the order book for Actuate Therapeutics Inc.Market Risk Summary & Community Consensus Picks - Newser
Regression Model Predicts Rangebound Movement in Blueprint Medicines Corporation2025 Market Outlook & High Conviction Buy Zone Picks - sundaytimes.kr
Actuate Therapeutics, Inc.: Strategic Regulatory Advances and Promising Clinical Data Drive Buy Rating - TipRanks
Actuate: HC Wainwright Raises PT to $20 from $15, Maintains Buy Rating - AInvest
Published on: 2025-08-18 02:08:11 - Newser
Should you hold or exit Actuate Therapeutics Inc. now2025 Retail Activity & Low Drawdown Investment Strategies - Newser
Using economic indicators to assess Actuate Therapeutics Inc. potentialRate Hike & Safe Swing Trade Setups - Newser
Identifying reversal signals in Actuate Therapeutics Inc.July 2025 Institutional & Accurate Technical Buy Alerts - Newser
Is a relief rally coming for Actuate Therapeutics Inc. holders2025 EndofYear Setup & Technical Pattern Based Signals - Newser
What the charts say about Actuate Therapeutics Inc. todayWeekly Profit Analysis & Free Weekly Chart Analysis and Trade Guides - Newser
How Actuate Therapeutics Inc. stock performs during market volatilityJuly 2025 Big Picture & Reliable Price Breakout Signals - mustnews.co.kr
Volatility clustering patterns for Actuate Therapeutics Inc.July 2025 Momentum & Risk Managed Investment Entry Signals - Newser
Actuate Therapeutics Inc Stock (ACTU) Financials Data
There is no financial data for Actuate Therapeutics Inc (ACTU). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Actuate Therapeutics Inc Stock (ACTU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | Director |
Jun 27 '25 |
Buy |
7.00 |
71,428 |
499,996 |
196,428 |
| Fletcher Aaron G.L. | Director |
Jun 27 '25 |
Buy |
7.00 |
71,428 |
499,996 |
196,428 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):